From behind the scenes of health‑tech innovation, a distinguished leader steps into the spotlight, her journey marked not by fanfare but by substance.
As founder and chief executive of a company that translates patient voices into actionable healthcare insights, Jo Halliday has been honoured with an MBE in the King’s Birthday Honours List of June 2025. This recognition, officially recorded as “Jo‑Anne HALLIDAY, Chief Executive Officer, Talking Medicines. For services to the Economy and to Medical Innovation”, reflects a remarkable convergence of entrepreneurship, data science and patient‑centric design.
Halliday’s work has consistently challenged the status quo in healthcare analytics. Under her leadership, her company pioneered solutions that harness unstructured patient narratives, such as forum discussions and social media comments, and transform them into structured insights. This empowers pharmaceutical companies and healthcare agencies to better understand real-world patient experiences, shaping drug development, marketing strategies, and policy decisions.
Rooted in a deep appreciation for both patient advocacy and commercial acumen, her vision has steered the business toward sustained growth. The company has expanded globally, attracting both industry interest and commercial partnerships across the US and Europe. Its tools go beyond passive data aggregation; they actively decode sentiment, unmet needs, and treatment patterns in real time, giving clients a clearer understanding of patient communities.
For investors, Halliday’s MBE signals more than a personal achievement; it emphasises the strategic value of a business operating at the intersection of technology, healthcare and regulation. Recognition from the Crown underscores the UK’s growing emphasis on innovation-driven economic growth and validation that patient‑focused data solutions hold national significance. That institutional endorsement is likely to reinforce trust among stakeholders across the healthcare industry, from regulators and payers to commercial partners.
Moreover, the accolade comes at a pivotal time. As regulators call for greater patient involvement in drug approval processes and healthcare systems become more reliant on real-world evidence, the need for platforms that systematically mine patient sentiment has only grown. Halliday’s firm is well positioned to ride this wave, backed by its leadership in natural language processing and AI applied to complex medical narratives—capabilities unveiled under her guidance earlier this year.
This honour also highlights a broader entrepreneurial narrative. Halliday has navigated the common tension between technological hype and actionable value, establishing credibility through validated outcomes rather than unsubstantiated promise. As a CEO, she has balanced the demands of scaling data solutions, securing partnerships, and safeguarding compliance, all while keeping the patient perspective central. It’s this measured yet ambitious approach that sets her apart and appeals to mission‑driven investors.
This recognition from the King’s Birthday Honours comes at a time when the health‑tech sector faces questions around scalability, regulatory scrutiny, and measurable impact. Halliday’s MBE suggests a resolution of those challenges—through a combination of technical rigour, commercial traction, and public legitimacy. For investors tracking companies that bridge healthcare, AI and patient engagement, it’s a signal worth noting.
Talking Medicines leverages AI and NLP to convert patient conversations into structured insights. Their platform helps pharmaceutical and healthcare agencies understand real-world treatment experiences, informing development, marketing, patient support, and policy, bringing the patient voice to the centre of decision-making.
Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.
